Armata Pharmaceuticals (ARMP) Stock Statistics & Valuation Metrics

Armata Pharmaceuticals has a market cap or net worth of $242.38M. The enterprise value is $270.88M.

Armata Pharmaceuticals has 36,229,843 shares outstanding. The number of shares has decreased by -2.65% in one year.

Armata Pharmaceuticals’s return on equity (ROE) is 0.39 and return on invested capital (ROIC) is -52.02%.

The current PE Ratio of Armata Pharmaceuticals is ―. Armata Pharmaceuticals’s PEG ratio is 0.05.

In the last 12 months, Armata Pharmaceuticals had revenue of 5.17M and earned -18.92M in profits. Earnings per share was -0.52.

In the last 12 months, operating cash flow was -27.02M and capital expenditures -413.00K, giving a free cash flow of -27.43M billion.

Armata Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Armata Pharmaceuticals upcoming earnings date is Mar 19, 2026, TBA (Confirmed).

Armata Pharmaceuticals as a current ratio of 0.23, with Debt / Equity ratio of -119.63%

In the past 12 months, Armata Pharmaceuticals has paid 0.00 in taxes.

Armata Pharmaceuticals EV to EBITDA ratio is -26.88, with an EV/FCF ratio of -4.67.

Armata Pharmaceuticals has $14.76M in cash and marketable securities with $114.35M in debt, giving a net cash position of -$99.60M billion.

Gross margin is 71.17%, with operating margin of -820.18%, and net profit margin of -365.60%.

The average price target for Armata Pharmaceuticals is $9.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy